We are advancing medicine by creating tests that help physicians provide personalized care with the right therapy for the right patient at the right time.

Leadership in oncology and reproductive testing
Genzyme has built one of the top five laboratories in the United States offering complex testing services to physicians and patients. We have established a leadership position in both reproductive and oncology testing by using 18 highly specialized technology platforms, supported by an experienced scientific staff and the largest network of board-certified genetic counselors in the nation.

We believe in the value of testing and envision a future where it will inform and reinforce therapeutic decisions. In 2005, we made personalized medicine a reality for more patients by launching three new cancer tests directly related to understanding a patient's response to targeted therapies - a link that is the basis of comprehensive cancer care. Each of these tests is the first or only one on the market. We added another such cancer test in early 2006. Together, they address forms of leukemia, lung cancer, and colorectal cancer.

We continue to lead the reproductive testing market, providing physicians with more choices and patients with more complete information. For example, in 2005 we expanded our cystic fibrosis (CF) mutation analysis to include 97 mutations to better serve the nation's ethnically diverse population with the most comprehensive and rapid test in the industry. Our enhanced CF mutation assay provides 21 percent higher detection for Hispanics and 9 percent higher for African Americans than the standard 23-mutation panel.

In 2006, we will continue to link our testing services more firmly to Genzyme's medical areas. We currently offer tests to diagnose and monitor treatment for Gaucher and Fabry patients, and soon we will provide testing to Pompe patients. Moving forward, we will continue to develop testing that supports the work of other medical areas.

Diagnostic tests and products
Genzyme continues its leadership role as a supplier of key raw materials and novel chemistry reagents to global partners serving the central hospital laboratory, concentrating on cardiovascular health. Expanding into the decentralized testing arena, we supply rapid tests with a focus on infectious diseases. In 2005, our rapid test to detect trichomonas infection, a common sexually transmitted disease that is largely undiagnosed and untreated, was granted CLIA waiver status by the FDA, allowing broader use at the point of care. Consistent with our drive to deliver value at the intersection of diagnostics and therapeutics, we are working with the tolevamer therapeutics team to develop a rapid test that will aid in the diagnosis of CDAD at the point of care.